Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Skin-Deep shot beat the needle for dengue protection?

NCT ID NCT06837116

Vaccine Sponsor: Prince of Songkla University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether giving the Qdenga dengue vaccine into the skin (intradermal) works as well as the standard shot under the skin. 29 healthy Thai adults who had never received a dengue vaccine took part. Researchers measured antibody and T-cell levels at day 0, 30, and 120 to compare immune responses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Qdenga dengue vaccine
What this could lead to
If successful, this could show that a smaller, intradermal dose of the dengue vaccine is effective, potentially making vaccination faster and easier.
What could go wrong
This is a very early pilot study with only 29 people, so results may not apply to larger populations. The intradermal route might not trigger a strong enough immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

29 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Thai adult aged 18-60 years, who not previously received dengue vaccine. * The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 3-month follow-up of the study. * Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization * The subject can provide with informed consent and sign informed consent form Exclusion Criteria: * Have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. * Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination. * Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. * Have acute infectious diseases, including dengue infection * Have severe chronic diseases or condition in progress cannot be controlled. For example, poor controlled DM and uncontrolled HT. * Have the history of urticaria 1 year before receiving the investigational vaccine. * Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). * Have needle sickness. * Have the history of immunosuppressive therapy, cytotoxic therapy or systemic corticosteroids * Have received blood products within 4 months before injection of investigational vaccines. * Under anti-tuberculosis treatment. * Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dengue are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dengue

Contacts and locations

Locations

  • Faculty of Medicine, Prince of Songkla University

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Prince of Songkla university

    Hat Yai, Changwat Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.